Ferroptosis, an iron-dependent form of cell death characterized by uncontrolled lipid
peroxidation, is governed by molecular networks involving diverse molecules and …

Palbociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer by suppressing
cell proliferation. However, monotherapy with palbociclib was discouraging in prostate …

Ferroptosis, an emerging paradigm of programmed cellular necrosis posited in recent years,
manifests across a spectrum of maladies with profound implications for human well-being …

Background Combination therapy involving immune checkpoint blockade (ICB) and other
drugs is a potential strategy for converting immune-cold tumors into immune-hot tumors to …

Abstract Currently, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved by
US Food and Drug Administration for BRCA-mutated pancreatic cancer therapy. However …

Cold atmospheric plasma (CAP) has exhibited exciting potential for cancer treatment.
Reactive oxygen and nitrogen species (RONS), the primary constituents in CAP, contribute …

A prominent cause of death among patients is cancer that can result from somatic mutations
and exposure to environmental factors, among others. The treatment of cancer has been …

Bromodomain-containing protein 4 (BRD4) is the most promising target for the treatment of
triple-negative breast cancer (TNBC). However, its inherent resistant and acquired drug …

Background NUAK family kinase 2 (NUAK2) has been identified as an important mediator
for tumor progression in multiple malignancies. Nevertheless, its role in lung …

The efficacy of CDK4/6 inhibitors as anti-tumor agents, especially in breast cancer, has been
constrained by direct treatment-associated toxicities and the development of drug …